Crossmark

ASO Visual Abstract: The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Crossref DOI link: https://doi.org/10.1245/s10434-023-14317-2

Published Online: 2023-10-03

Published Print: 2024-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Blumencranz, Peter

Habibi, Mehran

Shivers, Steve

Acs, Geza

Blumencranz, Lisa E.

Yoder, Erin B.

van der Baan, Bastiaan

Menicucci, Andrea R.

Dauer, Patricia

Audeh, William

Cox, Charles E.
License Information

Text and Data Mining valid from 2023-10-03

Version of Record valid from 2023-10-03
More Information

Article History

First Online: 3 October 2023

Disclosure

: Steve Shivers: Full-time employee of PreludeDx, a medical device company whose products are unrelated to this manuscript. Charles Cox: Research funding from Agendia, Paradigm, PreludeDX, and Cianna Medical. Consulting for Cianna Medical/Merit Medical. Speakers’ bureau from Myriad Genetics and Cardinal Health. Honoraria from Cianna Medical. Travel, accommodations, or other expenses paid by Myriad Genetics and Cianna Medical.

Document is current

Any future updates will be listed below